- Home
- AMS vs IGC Comparison
AMS vs IGC Comparison
Compare AMS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- IGC
- Stock Information
- Founded
- AMS 1980
- IGC 2005
- Country
- AMS United States
- IGC United States
- Employees
- AMS N/A
- IGC N/A
- Industry
- AMS Medical Specialities
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- IGC Health Care
- Exchange
- AMS Nasdaq
- IGC Nasdaq
- Market Cap
- AMS 19.3M
- IGC 19.1M
- IPO Year
- AMS N/A
- IGC N/A
- Fundamental
- Price
- AMS $2.80
- IGC $0.28
- Analyst Decision
- AMS
- IGC Strong Buy
- Analyst Count
- AMS 0
- IGC 2
- Target Price
- AMS N/A
- IGC $3.88
- AVG Volume (30 Days)
- AMS 27.6K
- IGC 415.4K
- Earning Date
- AMS 05-13-2025
- IGC 02-18-2025
- Dividend Yield
- AMS N/A
- IGC N/A
- EPS Growth
- AMS 779.12
- IGC N/A
- EPS
- AMS 0.61
- IGC N/A
- Revenue
- AMS $24,969,000.00
- IGC $1,236,000.00
- Revenue This Year
- AMS $27.74
- IGC N/A
- Revenue Next Year
- AMS $17.72
- IGC $18.34
- P/E Ratio
- AMS $4.69
- IGC N/A
- Revenue Growth
- AMS 20.83
- IGC 1.65
- 52 Week Low
- AMS $2.64
- IGC $0.26
- 52 Week High
- AMS $4.60
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- AMS 45.88
- IGC 40.22
- Support Level
- AMS $2.75
- IGC $0.29
- Resistance Level
- AMS $2.90
- IGC $0.30
- Average True Range (ATR)
- AMS 0.09
- IGC 0.02
- MACD
- AMS 0.01
- IGC -0.00
- Stochastic Oscillator
- AMS 37.50
- IGC 4.00
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.